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Background:  Proteinuria  and  reduced  estimated  glomerular  ﬁltration  rate  (eGFR)  are associated  with  an
increased  risk  of  mortality  from  acute  myocardial  infarction  (AMI).  However,  it  is  unknown  whether
there  is  a difference  in  prognostic  value  for all-cause  mortality  between  proteinuria  and  eGFR  during
post-AMI.
Methods:  A consecutive  series  of  101  patients  admitted  with  AMI  who  received  angioplasty  were
enrolled.  Dipstick  proteinuria  and  eGFR  were  assessed  on  admission:  (i) the patients  were  divided
into  2 groups  according  to the  presence  of proteinuria  (proteinuria,  n  =  25), or not  (negative,  n  =  76),
(ii)  the patients  were  divided  into  2 groups  according  to  lower  eGFR  (GFR  < 60 mL/min/1.73  m2,  n  =  31)  or
higher  (GFR  >  60  mL/min/1.73  m2, n  = 70).  Clinical  characteristics  and  3-year  all-cause  mortality  estimated
by  Kaplan–Meier  method  were  evaluated  in  each  group.  Additionally,  a  multivariate  Cox  proportional
hazards  model  was applied  to evaluate  which  factor  was associated  with  all-cause  mortality.
Results: Mean  follow-up  period  was  914  days.  Higher  brain  natriuretic  peptide  (BNP)  levels  were
shown  in  the  proteinuria  and  lower eGFR  groups,  respectively  (proteinuria,  301 ± 324 pg/mL; negative,
146  ± 159  pg/mL;  p = 0.02;  lower  eGFR,  294  ± 305  pg/mL;  higher  eGFR,  142  ±  161  pg/mL;  p =  0.02).  Three-
year  all-cause  mortality  was  higher  in  the proteinuria  group  than  in  the  normal  group  (p < 0.001)  and
in  the lower  eGFR  group  than  in the higher  group  (p = 0.006).  In a Cox  proportional  hazards  model,  the
presence  of  proteinuria  [hazard  ratio  (95%  conﬁdence  interval),  4.51  (1.07–18.96);  p  = 0.04]  was  selected
as  one  of the  predictors  for all-cause  mortality.
Conclusions: Dipstick  proteinuria  and  lower  eGFR  in the  early  phase  of  AMI  follow-up  were  related
to  increased  plasma  BNP  level  during  the sub-acute  phase  and  long-term  adverse  outcome.  Dipstick
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Microalbuminuria is deﬁned as a small amount of urinary albu-
in excretion (30–300 mg/day), and is an established risk factor
or cardiovascular events [1]. Indeed, previous studies have indi-
ated that any degree of microalbuminuria is a risk factor for
ardiovascular events, independent of the complications of dia-
etes mellitus [2]. Furthermore, several investigators have reported
he presence of early phase transient microalbuminuria in patients
uffering from acute myocardial infarction (AMI) is associated with
n increased risk of in-hospital and long-term mortality [3–7].On  the other hand, dipstick urinalysis is a convenient method
or assessing proteinuria [8,9]. A recent study showed that the risk
f major cardiovascular events and progression to renal failure
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are independently increased in patients with higher levels of pro-
teinuria [10]. However, whether dipstick proteinuria, especially
presented in the early phase of AMI, has a more prognostic value
for long-term mortality compared with estimated glomerular ﬁl-
tration rate (eGFR) has not been fully elucidated.
To clarify which has a more predictive value in AMI  patients
treated with emergent angioplasty, we  compared clinical data and
3-year all-cause mortality between the groups with and without
dipstick proteinuria, and between the groups of lower eGFR and
higher. We also evaluated the relationship between presence of
proteinuria and 3-year all-cause mortality using a multivariate Cox
proportional hazards model.
MethodsPatient population
A  consecutive series of 101 Japanese patients with AMI  admitted
to Asahikawa Medical University Hospital who  received emergent
vier Ltd. All rights reserved.
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oronary angioplasty from July 2006 to March 2011 were included
n the study. All patients underwent dipstick urinalysis (Siemens
ealth Care Diagnostics, Erlangen, Germany) during the early phase
f follow-up (up to 5 days from the onset of AMI). The ﬁrst morning
rine samples were collected. Proteinuria was deﬁned as a level
reater than “positive” (>30 mg/dL) on dipstick urinalysis. Patients
ere divided into 2 groups according to the presence or absence
f proteinuria; 25 patients were allocated to the positive group,
nd 76 patients were allocated to the negative group (negative or
race). Besides these cohorts, the patients were also divided into
 groups according to the eGFR on admission; 28 patients were
llocated to lower eGFR (GFR < 60 mL/min/1.73 m2) group, and 73
atients were higher eGFR (GFR > 60 mL/min/1.73 m2) group. We
onducted a retrospective cohort analysis using these groups and
ollowed their prognosis for up to 3 years from the onset of AMI.
eﬁnitions
AMI  was deﬁned as (i) creatine kinase (CK) or creatine kinase
B (CK-MB) levels elevated over 2-fold from the upper limit of our
aboratory standard and (ii) typical symptoms of ischemia and/or
lectrocardiographic changes indicative of new ischemia. Patients
ho were admitted to hospital after 24 h from the onset of AMI
ere excluded from the study.
rimary percutaneous coronary intervention procedure
Primary percutaneous coronary intervention (PCI) was per-
ormed via the transfemoral or transradial approach using a 6-
r 7-French-size guiding catheter. The operators carrying out PCI
hose to use manual thrombectomy devices, thrombolytic agents,
nd stents. Intra-aortic balloon pumps were used when a patient
as in an unstable hemodynamic condition. Patients received
00 mg  of ticlopidine or 300 mg  of clopidogrel and 100 mg  of
spirin as a loading dose in the emergency room, followed by
ual antiplatelet therapy with a maintenance dose for at least
 month. Other medications, including angiotensin-converting
nzyme  inhibitors (ACE-I), angiotensin II type 1 receptor blockers
ARBs), statins, diuretics, beta-blockers, and nicorandil, were also
rescribed as required.
ata  collection
Clinical parameters assessed included age, sex, smoking habit,
ypertension, diabetes mellitus, dyslipidemia, prior myocardial
nfarction, body mass index (BMI), eGFR, and Killip classiﬁcation.
ypertension was deﬁned as a blood pressure of >140/90 mmHg
r previous use of antihypertensive drugs. Diabetes mellitus was
iagnosed as a fasting plasma glucose level of >126 mg/dL, a 2-h
lasma glucose level of >200 mg/dL measured by oral glucose tol-
rance test, or previous use of hypoglycemic drugs. Dyslipidemia
as deﬁned as a serum total cholesterol level of >220 mg/dL, a
erum triglyceride level of >150 mg/dL, or previous use of lipid-
owering drugs. eGFR (mL/min/1.73 m2) was calculated using the
quation 194 × plasma creatinine (mg/dL)−1.094 × age (years)−0.287
for males) × 0.739 (for females) [11]. Contrast-induced nephropa-
hy (CIN) was deﬁned as an absolute increase in serum creatinine
.5 mg/dL and/or a relative increase in serum creatinine 25%.
lasma brain natriuretic peptide (BNP) levels were measured in
he sub-acute phase (2–4 weeks from the onset of AMI). Patients
nderwent transthoracic echocardiographic examination to assess
eft ventricular (LV) dimension and contractility after 2–4 weeks
rom the onset of AMI. LV ejection fraction (EF) was calculated from
pical 4-chamber and 2-chamber views by the modiﬁed Simpson
ethod. Major bleeding included fetal bleeding, intracranial hem-
rrhage, and bleeding that was treated with transfusion of 2 orlogy 62 (2013) 277–282
more  units of red blood cell. All-cause mortality was determined
by medical records, direct interview, and telephone survey. Car-
diovascular deaths included sudden death and deaths from heart
failure, arrhythmia, mechanical complications after AMI, and cere-
brovascular disease.
Statistical  analysis
Categorical data are presented as number and percentage; the
data were compared between the groups using the Fisher’s exact
test. Continuous data are presented as mean ± standard deviation;
the data were compared using a t-test. Time until all-cause mor-
tality was described using Kaplan–Meier analysis and compared
with the log-rank test. To identify predictors for all-cause mor-
tality after AMI, a multivariate Cox proportional hazards model
(stepwise forward method) was  applied with the variables of
p < 0.10 in the univariate analysis. The baseline covariates were
BMI, dyslipidemia, Killip III or IV, heart rate, systolic blood pressure,
hemoglobin concentration, total cholesterol level, C-reactive pro-
tein level, statin, GFR < 60 mL/min/1.73 m2, and proteinuria. Since
aging and diabetes mellitus are well known powerful prognostic
factors after AMI  [12], the analysis was  adjusted for age and preva-
lence of diabetes mellitus. Results are described as hazard ratio (HR)
with 95% conﬁdence intervals (CI). A p-value of <0.05 was consid-
ered signiﬁcant. Statistical analyses were performed with IBM SPSS
version 18.0 (Chicago, IL, USA).
Results
Clinical characteristics of proteinuria group and lower eGFR group
Patient characteristics classiﬁed by proteinuria and eGFR are
shown in Table 1. The proteinuria group showed older age, lower
BMI, lower prevalence of dyslipidemia, lower total cholesterol level,
and lower blood pressure in the emergency room than those with
normal values. Lower hemoglobin and eGFR on admission were
found in the proteinuria group. Around 80% of the proteinuria group
turned to negative or trace of proteinuria in the sub-acute phase of
follow-up.
Lower eGFR (GFR < 60 mL/min/1.73 m2) group also showed older
age, lower total cholesterol level, lower hemoglobin, and lower
blood pressure in the emergency room than the higher eGFR
(GFR > 60 mL/min/1.73 m2) group. However, higher tendency in
prevalence of diabetes was  found in the GFR < 60 group, although
there was  no difference in the prevalence of dyslipidemia. Protein-
uria was more frequent in the GFR < 60 group, but 13 patients with
proteinuria (18%) were found in the GFR > 60 group.
Although intra-aortic balloon pumps were used more frequently
in the proteinuria group, onset-balloon time and rate of stent
implantation did not differ in the proteinuria group compared
with the normal group and in the GFR < 60 group compared with
the GFR > 60 group, respectively. Prescribed drugs at discharge are
shown in Table 2. Statins were used less frequently in the pro-
teinuria group and in the GFR < 60 group, respectively. In addition,
ACE-I was  used less frequently in the proteinuria group. By contrast,
diuretics were used more frequently in the GFR < 60 group.
As for parameters of sub-acute phase cardiac function, mean
plasma BNP levels were signiﬁcantly higher in the proteinuria
group and the GFR < 60 group. Echocardiographic LVEF was signiﬁ-
cantly lower in the proteinuria group than the normal-value group.
The GFR < 60 group showed relatively lower LVEF, although that did
not reach signiﬁcance (Table 3).
In this study, mean follow-up period was 914 ± 288 days
(253 person-years). Contrast-induced nephropathy occurred more
frequently in the proteinuria group and the GFR < 60 group,
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Table  1
Patient characteristics.
Proteinuria Negative p GFR < 60 GFR > 60 p
(n = 25) (n = 76) (n = 28) (n = 73)
Age (year) 71 ± 12 65 ± 13 0.046 73 ± 9 64 ± 13 <0.001
Sex  (female, %) 2 (8) 19 (25) 0.09 5 (18) 16 (22) 0.79
BMI  (kg/m2) 22.7 ± 3.2 24.4 ± 3.6 0.04 23.0 ± 3.0 24.3 ± 3.7 0.10
Hypertension (%) 18 (72) 56 (74) 1.00 20 (71) 54 (74) 0.81
Diabetes  mellitus (%) 8 (32) 28 (37) 0.81 14 (50) 22 (30) 0.07
Dyslipidemia  (%) 16 (64) 65 (86) 0.04 21 (75) 60 (82) 0.42
Current  smoker (%) 8 (33) 36 (47) 0.25 11 (39) 33 (46) 0.66
Prior  MI  (%) 2 (8) 2 (3) 0.26 1 (4) 3 (4) 1.00
Killip  III or IV (%) 5 (20) 5 (7) 0.12 6 (21) 4 (6) 0.03
Systolic  BP (mmHg) 128 ± 23 151 ± 33 0.005 132 ± 47 151 ± 29 0.06
Heart  rate (beats/min) 71 ± 23 78 ± 20 0.18 72 ± 24 77 ± 20 0.22
Door-Balloon (min) 82 ± 38 134 ± 170 0.01 102 ± 111 129 ± 163 0.43
Onset-Balloon (min) 374 ± 414 377 ± 336 0.97 343 ± 341 389 ± 362 0.56
LAD culprit (%) 12 (48) 38 (50) 1.00 9 (32) 41 (56) 0.045
Stent  (%) 25 (100) 71 (93) 0.33 27 (96) 69 (95) 1.00
Bare-metal  stent (%) 25/25 (100) 70/71 (99) 1.00 27/27 (100) 68/69 (99) 1.00
Stent  diameter (mm) 3.09 ± 0.44 3.08 ± 0.37 0.92 3.10 ± 0.47 3.08 ± 0.35 0.77
Stent  length (mm) 24.2 ± 9.9 19.3 ± 5.1 0.03 20.3 ± 5.9 20.7 ± 7.4 0.80
IABP  (%) 4 (16) 2 (3) 0.03 3 (11) 3 (4) 0.34
Final  TIMI3 ﬂow (%) 23 (92) 68 (90) 1.00 27 (96) 64 (88) 0.28
Contrast  (mL) 151 ± 65 145 ± 52 0.60 135 ± 39 151 ± 60 0.21
Laboratory  data
Hemoglobin (g/dL) 13 ± 2 14 ± 2 0.02 13 ± 2 14 ± 2 <0.001
Glucose  (mg/dL) 199 ± 110 161 ± 60 0.12 190 ± 100 163 ± 64 0.12
Total  cholesterol (mg/dL) 179 ± 37 214 ± 63 0.01 183 ± 48 214 ± 62 0.02
C-reactive  protein (mg/dL) 0.7 ± 1.3 0.5 ± 1.2 0.46 0.6 ± 1.2 0.5 ± 1.2 0.68
eGFR  (mL/min/1.73m2) 59 ± 22 73 ± 21 0.005 44 ± 12 79 ± 16 <0.001
Proteinuria  (acute, %) 25/25 (100) 0/76 (0) <0.001 12/28 (43) 13/73 (18) 0.02
Proteinuria  (sub-acute, %) 4/19  (21) 3/71 (4) <0.03 3/22 (14) 4/68 (6) 0.36
Peak  CK (IU/L) 2998 ± 1862 2755 ± 1919 0.59 2684 ± 1674 2864 ± 1989 0.67
Peak  CK-MB (IU/L) 280 ± 171 277 ± 197 0.94 245 ± 153 290 ± 202 0.29
BMI, body mass index; MI,  myocardial infarction; BP, blood pressure; LAD, left anterior descending artery; IABP, intra-aortic balloon pumps; TIMI, thrombolysis in myocardial
infarction; eGFR, estimated glomerular ﬁltration rate; CK, creatinine kinase.
Table 2
Medications at discharge.
Proteinuria Negative p GFR < 60 GFR > 60 p
Beta-blocker (%) 10 (42) 44 (58) 0.24 11 (39) 43 (60) 0.08
ACE-I  (%) 8 (33) 45 (59) 0.04 12 (43) 41 (57) 0.27
ARB  (%) 8 (33) 23 (30) 0.80 9 (32) 22 (31) 1.00
CCB  (%) 6 (25) 20 (26) 1.00 6 (21) 20 (28) 0.62
Diuretic  (%) 9 (38) 17 (22) 0.18 14 (50) 12 (17) 0.002
Statin  (%) 12 (50) 68 (90) <0.001 17 (61) 63 (88) 0.005
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin II type 1 receptor blocker; CCB, Ca channel blocker.
Table 3
Cardiac function and adverse outcomes.
Proteinuria Negative p GFR < 60 GFR  > 60 p
Sub-acute phase cardiac function
BNP (pg/mL) 301 ± 324 146 ± 159 0.02 294 ± 305 142 ± 161 0.02
LVEF  (%) 52 ± 12 57 ± 9 0.02 54 ± 13 57 ± 9 0.17
Adverse  outcomes
CIN  (%) 4 (17) 0 (0) 0.003 3 (11) 1 (1) 0.07
Major  bleeding (%) 4 (16) 4 (5) 0.10 4 (14) 4 (6) 0.21
In-hospital  death (%) 3 (12) 0 (0) 0.14 2 (7) 1 (1) 0.19
3-yr  cardiovascular death (%) 4 (16) 2 (3) 0.03 4 (14) 2 (3) 0.048
3-yr  all-cause death (%) 9 (36) 3 (4) <0.001 7 (25) 5 (7) 0.02
Causes  of death
Heart  failure 2 1 2 1
Sudden  death 0 1 1 0
Ventricular septal perforation 1 0 0 1
Cardiac  rupture 1 0 1 0
Malignancy 3 0 0 3
Infection  1 1 2 0
Hemoptysis 1 0 1 0
BNP, brain natriuretic peptide; LVEF, left ventricular ejection fraction; CIN, contrast-induced nephropathy.
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espectively. Twelve all-cause deaths and six cardiovascular deaths
ccurred over the period of follow-up. The incidence of 3-year all-
ause deaths and cardiovascular deaths was signiﬁcantly higher
n the proteinuria group and the GFR < 60 group, respectively
Table 3). Figs. 1 and 2 show Kaplan–Meier curves for all-cause mor-
ality stratiﬁed by proteinuria and eGFR. Probability of all-cause
ig. 1. Kaplan–Meier survival curves stratiﬁed by grades of proteinuria. Solid line
epresents the negative group; broken line, the proteinuria group; and +, censoring.
umulative  mortality of the proteinuria group was signiﬁcantly higher than the
egative group (p < 0.001 by log-rank test).
ig. 2. Kaplan–Meier survival curves stratiﬁed by grades of estimated glomerular ﬁl-
ration rate (eGFR). Solid line represents the higher eGFR (GFR >60 mL/min/1.73 m2)
roup; broken line, the lower eGFR (GFR < 60 mL/min/1.73 m2) group; and + censor-
ng. Cumulative mortality of the lower eGFR group was  signiﬁcantly higher than the
igher eGFR group (p = 0.006 by log-rank test).logy 62 (2013) 277–282
mortality was  signiﬁcantly higher in the proteinuria group and
the GFR < 60 group, respectively. A multivariate Cox proportional
hazards model was  applied to identify predictors of all-cause mor-
tality after AMI. Dyslipidemia and presence of proteinuria were
selected as predictive factors (Table 4).
Discussion
In this study we demonstrated that dipstick proteinuria in the
acute setting as well as lower eGFR were related to lower cardiac
function and adverse outcomes after AMI  treated with interven-
tional reperfusion therapy. Our results also suggested that dipstick
proteinuria and lower frequency of dyslipidemia were associated
with 3-year all-cause mortality.
Reduced  eGFR has already been believed to be associated with
poor prognosis for patients after myocardial infarction. McCullough
pointed out 3 reasons: increased bleeding risk; contrast-induced
nephropathy; and special biologic processes such as endothelial
dysfunction [13]. Our data showed major bleeding events did
not differ between the cohorts, but presence of contrast-induced
nephropathy increased in the proteinuria group and lower eGFR
groups, respectively. Contrast-induced nephropathy might affect
all-cause mortality in some part, however the incidence was very
small.
On the other hand, several investigators have reported the pre-
dictive value of transient increase of urinary albumin for adverse
prognosis in the acute setting after myocardial infarction. Berton
et al. conducted a prospective cohort study with 432 AMI patients.
They reported that albumin excretion rate increased transition-
ally during the acute phase of AMI. In addition, the incidence of
7-year mortality was  related to albumin-to-creatinine ratio on
the third day [4,5]. Lambert et al. investigated 1-year all-cause
mortality in 956 non-stage 5 chronic kidney disease patients
with AMI. They found that a cohort of patients with an eGFR
of 15–59 mL/min/1.73 m2 accompanying dipstick proteinuria of
>30 mg/dL was associated with all-cause mortality [HR (95% CI),
2.68 (1.34–5.37)] using multivariate analysis, however, a cohort of
proteinuria ≥30 mg/dL did not reach statistical signiﬁcance as an
independent risk factor in the study [14].
Tonelli et al. also investigated all-cause mortality in 4098
AMI survivors after 58.9 months of follow-up in their choles-
terol and recurrent events (CARE) study. They found that dipstick
proteinuria was  an independent predictor of all-cause mortal-
ity, with or without impaired kidney function [proteinuria and
GFR > 60 mL/min/1.73 m2, HR (95% CI), 1.43 (1.14–1.81); protein-
uria and GFR < 60 mL/min/1.73 m2, HR (95% CI), 1.84 (1.35–2.50)]
[15]. However, the dipstick proteinuria measured in the study was
not performed in the acute phase of the AMI  follow-up. So this
should be considered as another result of relationship between
proteinuria and ischemic heart disease. The transient increase in
urinary albumin excretion rate during AMI  may  be a response to
the systemic inﬂammatory process accompanying AMI  [5].
Although  the mechanisms responsible for the association
between proteinuria in AMI  and poor prognosis remain unclear,
several pathophysiological conditions such as endothelial dys-
function, inﬂammation, and hemodynamic impairment have been
suggested to explain the relationship in previous reports [1,3–7,16].
Endothelial dysfunction and inﬂammation represent important
potential mechanisms. In their Steno hypothesis, Deckert et al.
proposed that albuminuria reﬂects widespread vascular damage
[17]. Impaired endothelial function and inﬂammatory changes
are suggested to increase vascular permeability and cause leak-
age of albumin. Therefore, albuminuria or dipstick proteinuria
observed in the kidney vessels may  reﬂect systemic vascular
damage.
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Table  4
Cox  proportional hazards analyses for all-cause mortality.
Univariate analysis Multivariate analysis
HR (95% CI) p HR (95% CI) p
Age 1.11 (1.03–1.18) 0.003 1.08 (1.01–1.16) 0.03
Female  sex 0.33 (0.04–2.58) 0.29 –
Body  mass index 0.72 (0.57–0.90) 0.004 –
Medical history
Hypertension 1.03 (0.28–3.79) 0.97 –
Diabetes mellitus 1.37 (0.44–4.32) 0.59 2.30 (0.57–9.40) 0.25
Dyslipidemia  0.11 (0.03–0.35) <0.001 0.12 (0.03–0.49) 0.003
Current  smoker 0.46 (0.12–1.72) 0.25 –
Prior  myocardial infarction 2.61 (0.34–20.21) 0.36 –
Index admission
Killip  III or IV 4.13 (1.11–15.31) 0.03 –
Heart rate 0.97 (0.94–1.00) 0.045 –
Systolic blood pressure 0.98 (0.94–0.99) 0.003 –
LAD culprit 0.99 (0.32–3.07) 0.99 –
Stent length 1.05 (0.99–1.10) 0.11 –
Hemoglobin 0.70 (0.53–0.93) 0.01 –
Total cholesterol 0.97 (0.95–0.99) 0.001 –
C-reactive  protein 1.28 (1.00–1.65) 0.05 –
GFR < 60 4.32 (1.37–13.65) 0.01 –
Proteinuria 10.98 (2.97–40.58) <0.001 4.49 (1.08–18.76) 0.04
Medication
ACE-I  0.70 (0.21–2.28) 0.55 –
Beta-blocker 0.66 (0.20–2.15) 0.48 –
Diuretic 2.49 (0.76–8.17) 0.13 –
Statin  0.07 (0.02–0.26) <0.001 –
HR, hazard ratio; CI, conﬁdence interval; LAD, left anterior descending artery; GFR, glomerular ﬁltration rate; ACE-I, angiotensin-converting enzyme inhibitor.
The covariates for the multivariate analysis adjusted for age and prevalence of diabetes mellitus were selected from the following factors using stepwise forward method: body
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In the sub-acute phase, proteinuria was observed in 7 patients,
nd persistent proteinuria from acute phase to sub-acute phase was
bserved in 4 of them in this study. Most of these patients suffered
rom organic kidney disease such as glomerulonephritis, nephrotic
yndrome, and diabetic nephropathy. Among these patients, only
ne patient with nephrotic syndrome in the proteinuria group and
he GFR >60 group died from malignancy. Since patients with per-
istent proteinuria tend to have had organic kidney diseases, their
roteinuria may  not always be associated with systemic endothe-
ial dysfunction or systemic vascular damage.
Proteinuria is considered a comprehensive marker of systemic
athophysiological changes. Dipstick urinalysis of protein is cost
ffective and easy to perform. In addition, dipstick proteinuria may
lso play a role as a speciﬁc prognostic tool, allowing the detection
f impaired cardiac function and long-term mortality after AMI.
long with many studies reporting useful predictors of adverse
linical outcomes in acute coronary syndrome [18–20], the dipstick
roteinuria may  also be a convenient surrogate marker to predict
mpairment of cardiac function and long-term poor prognosis in
atients after AMI.
This  study has several limitations. First, all these acute phase
rine samples were collected up to 5 days from admission, but the
ates of collection were dispersed throughout this period. There
ay have been a difference in the degree of proteinuria between the
amples collected earlier and those collected later. And if the urine
s diluted with hydration, the dipstick may  turn to be false nega-
ive. A spot protein/creatinine ration might be more informative.
econdly, there were several differences in the clinical characteris-
ics in the cohorts. Medications at discharge were similar between
he groups, except that statin prescription was signiﬁcantly lower
n the proteinuria group and lower eGFR group, and ACE-I prescrip-
ion was signiﬁcantly lower in the proteinuria group. The reason for
he lower frequency of statin prescription may  be partially related
o the patient’s nutritional status; hemoglobin concentration and
otal cholesterol level were signiﬁcantly lower in the proteinuriancentration, total cholesterol, c-reactive protein, GFR < 60, presence of proteinuria,
group  and lower eGFR group, respectively. Therefore, there may
have been little need to use a statin for the patients in these cohorts.
Meanwhile, an appropriate reason was not found to explain the
lower rate of ACE-I prescription. We  speculate that lower systemic
blood pressure in the proteinuria group may  be the cause of this
result. Thirdly, the present study is limited by a single center and a
small number of patients. A multicenter study with a larger number
of patients is needed to conﬁrm these ﬁndings.
In conclusion, the presence of dipstick proteinuria and reduced
eGFR in the early phase of AMI  follow-up were related to adverse
outcomes and an increase in plasma BNP level and a decrease in
LVEF during the sub-acute phase. The presence of dipstick pro-
teinuria was  selected as one of the predictive markers for 3-year
all-cause mortality in a multivariate Cox proportional hazards
model. Dipstick proteinuria may  be a cost effective and an easy-
to-perform surrogate marker during AMI  follow-up.
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